Author of

• 35377

  +

  P14 - Immuno-biology and Novel Immunotherapeutics (Phase I and Translational) - Immuno-Biology (ID 153)

  • Event: WCLC 2020
  • Type: Posters
  • Track: Immuno-biology and Novel Immunotherapeutics (Phase I and Translational)
  • Presentations: 1
  • Moderators:
  • Coordinates: 1/28/2021, 00:00 - 00:00, ePoster Hall

  • 35416

    +

    P14.25 - Immune Cell Profiling of Hyperprogressive Disease in Patients with Non-Small Cell Lung Cancer Treated with Anti-PD-1/PD-L1 Antibodies (ID 3272)

    00:00 - 00:00  |  Presenting Author(s): Kyung Hwan Kim
    • Abstract
    • Slides

    Introduction
    

    Hyperprogressive disease (HPD) is a distinct pattern of progression characterized by acceleration of tumor growth after treatment with anti-PD-1/PD-L1 antibodies. However, the immunological characteristics have not been fully elucidated in patients with HPD. In the present study, we aimed to uncover the immunological characteristics specific to HPD using peripheral blood obtained before and early after anti-PD-1/PD-L1 treatment in patients with non-small cell lung cancer (NSCLC).

    Methods
    

    We prospectively recruited patients with metastatic non-small cell lung cancer treated with anti-PD-1/PD-L1 antibodies between April 2015 and April 2018, and collected peripheral blood before treatment and 7-days post-treatment. HPD was defined as ≥ 2-fold increase in both tumor growth kinetics and tumor growth rate between pre-treatment and post-treatment. From peripheral blood mononuclear cells, CD8⁺ and CD4⁺ T cells, regulatory T cells, and myeloid derived suppressor cells were analyzed by multi-color flow cytometry.

    Results
    

    Of 115 patients, 19 (16.5%) developed HPD, 52 experienced durable clinical benefit (DCB; partial response or stable disease ≥6 months), and 44 experienced non-hyperprogressive progression (NHPD). Patients with HPD had significantly lower progression-free survival (P < 0.001) and overall survival (P < 0.001). A total of 72 immune cell parameters were analyzed and the pre-treatment frequency of CD39⁺ cells among CD8⁺ T cells was significantly higher in patients with HPD compared to those with NHPD. Other parameters regarding the proliferative response or frequency of total regulatory T cells, effector regulatory T cells (FoxP3^hiCD45RA^-) or myeloid derived suppressor cells did not significantly differ among DCB, NHPD, and HPD groups.

    Conclusion
    

    Our findings suggest high pre-treatment frequency of CD39⁺CD8⁺ T cells might be a characteristic of HPD. Further investigations in a larger cohort are needed to confirm our results and better delineate the immune landscape of HPD.

    Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.